By Sneha S K and Sahil Pandey
Dec 31 (Reuters) - The U.S. Food and Drug Administration has declined to approve Corcept Therapeutics' drug for the treatment of a rare hormonal disorder, the company said on Wednesday.
Shares of the drugmaker were down 48% at $36.41.
The company said the FDA could not arrive at a favorable benefit-risk assessment for the hormone-blocking oral treatment, known as relacorilant, without Corcept providing additional evidence of effectiveness.
The company was seeking approval for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism.
"FDA's request for additional data may require additional trials, significantly dimming Corcept's outlook in Cushings," said Truist analyst Joon Lee.
Hypercortisolism, also known as Cushing's syndrome, occurs when the body is exposed to high cortisol activity.
Corcept had submitted trial data that showed that relacorilant made improvements in a wide array of hypercortisolism's signs and symptoms.
"We will meet with the FDA as soon as possible to discuss the best path forward," said Joseph Belanoff, Corcept's CEO.
Main symptoms of hypercortisolism include a fatty hump between the shoulders, a rounded face, and pink or purple stretch marks on the skin. People with Cushing's also experience diabetes, high blood pressure, muscle weakness and immune suppression.
Relacorilant is a selective cortisol modulator designed to block the effects of cortisol, while avoiding certain off‑target hormonal effects.
"Given the company had opportunities to address FDA's concerns during mid and late-stage reviews, it's unclear if any further dialogue can resolve the review issues without additional trials," Lee added.
Corcept is also studying the drug in a variety of serious disorders including ovarian and prostate cancer. Its other drug known as Korlym is approved to treat high blood sugar caused by hypercortisolism in adults with endogenous Cushing's syndrome.
Other approved treatments for Cushing's syndrome include Isturisa by Recordati and Xeris Biopharma's Recorlev.
(Reporting by Sahil Pandey and Sneha S K in Bengaluru; Editing by Shailesh Kuber)
LATEST POSTS
- 1
Find the Advantages of Innovative Leisure activities: Supporting Creative mind and Self-Articulation - 2Moon-bound Artemis II astronauts enjoy a relaxed day in space
- 3Flight cancellations: Full list of 40 airports hit by FAA cuts amid government shutdown
- 4The last penny was pressed by the U.S. Mint in Philadelphia today. Could the nickel and dime be next?
- 5Why do people get headaches and migraines? A child neurologist explains the science of head pain and how to treat it
- ‘Wu-Tang Forever: The Final Chamber’ tour — How to get tickets, presale times, concert dates and more
- Gunmen open fire near Israeli consulate in Istanbul in possible ISIS-linked attack
- The most effective method to Help a Friend or family member Determined to have Cellular breakdown in the lungs
- Sanofi to acquire hepatitis B vaccine maker Dynavax for $2.2 billion
- Iran executes two men who tried storming military facility during January protest crackdown
- Which European countries have mandatory or voluntary military service
- Which Carrier Do You Suggest? Vote
- Vote in favor of your Favored kind of pasta
- Top 20 Wellbeing and Wellness Applications for a Sound Way of life
